US/UK/Canada

Share

Pick a time period -
Tags ( Active)

AkzoNobel acquires majority ownership of Japanese joint venture

AkzoNobel has agreed to acquire a 75/25 majority interest in its Kayaku Akzo Co. Ltd (KAC) joint venture with Nippon Kayaku.KAC has been a 50/50 joint venture between the two companies for nearly 40 years. A leading supplier of organic peroxides to Japan, the business has sales offices in Tokyo and Osaka, Japan, as well as a manufacturing and research and development facility in Asa.“This opportunity allows AkzoNobel to gain access to the Japanese market and take on the leadership in the longstanding cooperation,” said Rob Frohn, Board member responsible for AkzoNobel Specialty Chemicals.

AkzoNobel completes REACH pre-registration

AkzoNobel has submitted its list of substances in compliance with the European Union’s REACH legislation.The company completed the process ahead of the December 1 cut-off date and has pre-registered around 6,000 substances following the introduction of the directive in June 2007.REACH (the EU’s regulation on the Registration, Evaluation, Authorization and Restriction of Chemicals) will transform the European chemical industry and will have profound implications for global chemical markets. Under the terms of the legislation, all chemicals of one ton or more in volume manufactured in – or

AkzoNobel opens Elotex production facility in China

AkzoNobel Functional Chemicals has officially opened a new production site in Shanghai, China, for its Elotex building material additives business.The facility, which produces redispersible powder polymers, has an annual capacity of around 20,000 tons and brings the total number of Elotex manufacturing plants worldwide to five.“The new manufacturing plant in Shanghai is primarily focused to better serve our Chinese and Asia Pacific customers for Elotex products,” said Rob Frohn, the AkzoNobel Board member responsible for Specialty Chemicals. “The completion of this project is another

Akzo Nobel divests PVC additives business

Arnhem, the Netherlands, March 15, 2007 — Akzo Nobel has divested its Akcros Chemicals PVC additives business to UK-based private investment firm GIL Investments. Financial details were not disclosed.Under the terms of the deal, the company’s sites in Eccles, UK, and New Brunswick in the United States—along with all of the approximately 160 employees at these locations—will be transferred to the new owner.An agreement has also been reached whereby Akzo Nobel will continue to operate two smaller, related production operations in Greiz, Germany, and Itupeva in Brazil. Employees at these two

Historic joint launch for Akzo Nobel’s flagship reports

Arnhem, the Netherlands, March 14, 2007 — Akzo Nobel has today published its Annual and Corporate Social Responsibility Reports for 2006—the first time that the company has launched both publications on the same day.Highlighting Akzo Nobel’s commitment to maintaining transparent and effective stakeholder communication, the joint launch not only emphasizes the importance of CSR to the whole organization, but is also an indication of the strong link the company is forging between economic success and delivering sustainable solutions.“Publishing our two most important reports together is a

Akzo Nobel Announces Intended Sale of Organon BioSciences to Schering-Plough for EUR 11 billion

Arnhem, the Netherlands, March 12, 2007 – Akzo Nobel is pleased to announce that on March 11, 2007, it received an offer for the purchase of its wholly owned subsidiary Organon BioSciences N.V. (OBS) from Schering-Plough for EUR 11 billion in cash. As a result, Akzo Nobel will no longer be proceeding with the partial IPO of OBS on Euronext Amsterdam.The Board of Management and the Supervisory Board of Akzo Nobel met yesterday, March 11, to consider the binding cash offer for OBS from Schering-Plough. After careful consideration it was concluded that this cash offer represents full value to

Akzo Nobel approves separation and Board changes

Arnhem, the Netherlands, March 1, 2007 — Following on from the recent announcement regarding the impending separation of the company, Akzo Nobel’s Board of Management and Supervisory Board formally decided, on February 28, to divest a minority stake in Organon BioSciences through a listing of approximately 20 to 30 percent of Organon BioSciences shares on Euronext Amsterdam.In addition, the company today also announced several changes in the Board of Management and the Supervisory Board. Toon Wilderbeek, the Akzo Nobel Board of Management member responsible for Pharma, has resigned as of

Akzo Nobel confirms IPO timing of Organon BioSciences

Arnhem, the Netherlands, Monday, February 26 - Akzo Nobel today confirms the start of the process to list Organon BioSciences N.V. (OBS) on Euronext Amsterdam. Investor pre-marketing is intended to take place during the first two weeks of March, with the management roadshow expected to commence shortly thereafter.Akzo Nobel intends to proceed with the initial public offering of shares of OBS and plans to list these shares before the end of March 2007, subject to financial market conditions. Further announcements relating to the IPO, including information on when and how the prospectus will

Akzo Nobel reconfirms listing of Organon BioSciences

Arnhem, the Netherlands, January 25, 2007 — Akzo Nobel has previously announced its intention to separate its Pharma business, preferably through a listing of approximately 20 to 30 percent of Organon BioSciences shares on Euronext in Amsterdam in early 2007.Over the last few weeks, Akzo Nobel has received preliminary expressions of interest from a number of parties regarding an acquisition of Organon BioSciences.Akzo Nobel has carefully reviewed these preliminary proposals from the perspective of long-term shareholder value creation. Taking into consideration the interests of all

Akzo Nobel agrees to sell 50 percent stake in Flexsys

Arnhem, the Netherlands, December 15, 2006 — Akzo Nobel has reached an agreement in principle to sell its 50 percent stake in rubber chemicals business Flexsys to joint venture partner Solutia Inc. Financial details were not disclosed.The proposed deal also includes the sale of Akzo Nobel’s toll manufacturing operation for Flexsys at the company’s Kashima site in Japan.“The recent realignment of our Chemicals portfolio concentrated our focus on core business,” explained Leif Darner, Akzo Nobel’s Board member responsible for Chemicals. “Our stake in Flexsys no longer fitted in with our

Akzo Nobel rejects damages claim

Arnhem, the Netherlands, December 1, 2006 — In its decision of December 10, 2003, the European Commission established that several companies, including Akzo Nobel, violated the EU competition rules before 2000.BASF and Basell have informed Akzo Nobel that they hold Akzo Nobel and other companies involved liable for damages they allege to have suffered as a result of these violations. BASF alleges that its aggregate damages exceed EUR 140 million (excluding interest and costs) and Basell alleges that it has suffered EUR 28.2 million (excluding interest and costs).Akzo Nobel considers these

Organon continues with the development of asenapine

Arnhem, The Netherlands, November 28, 2006 — Organon has decided to continue with the development of asenapine. This follows on from the decision taken by Organon and Pfizer to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.The results of the final Phase III clinical trial with respect to schizophrenia, which were recently received, were positive. This is in addition to the previous positive data on safety and tolerability for this indication. Organon will now

Joint press release - Organon and Pfizer discontinue their collaboration on asenapine

New York, New York, USA, November 28, 2006 and Arnhem, The Netherlands, November 28, 2006 — Organon and Pfizer today announced that they have agreed to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.Pfizer’s decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its overall portfolio. Pfizer will return all product rights, intellectual property and data to Organon and

Akzo Nobel appoints Dr. Jörg Spiekerkötter as CFO of Organon BioSciences N.V.

Arnhem, the Netherlands, October 26, 2006 — Akzo Nobel has appointed Dr. Jörg Spiekerkötter as Chief Financial Officer of its subsidiary Organon BioSciences N.V. He will officially take up the position on November 1, 2006. He will also be nominated for appointment as a member of the Board of Management of Organon BioSciences N.V.Mr. Spiekerkötter (48) will join Organon BioSciences from Schering AG, where he was a member of the Executive Board responsible for Finance, Administration and Human Resources. His appointment marks an important landmark in the establishment of Akzo Nobel’s Pharma

Akzo Nobel CEO outlines new strategy and targets at company’s Fit For the Future conference

Arnhem, the Netherlands, October 19, 2006 — Akzo Nobel has announced strategic plans designed to accelerate profitable growth and drive the company’s ongoing commitment to establishing leadership positions in key coatings and chemicals markets around the world.Speaking to investors, analysts and the media at the company’s Fit For the Future conference in London today, CEO Hans Wijers unveiled the company’s growth strategy and new targets for the next three years.“We have developed a comprehensive, highly focused strategy for our Coatings/Chemicals activities which will launch Akzo Nobel

Akzo Nobel secures license for breakthrough aerospace primer technology

Arnhem, the Netherlands, October 16, 2006 - Akzo Nobel’s Aerospace Coatings business (ANAC) has announced that it is the first to develop products to contain breakthrough chromate-free technology following the signing of a commercial licensing agreement with the North Dakota State University Research Foundation (NDSU).Researchers at NDSU have developed new primer technology for coating aluminum aircraft structures which is based on magnesium, rather than chromate (a harmful substance which is highly regulated in the U.S. and is coming under increasing pressure in Europe). This pioneering

Intervet supports ECVIM-CA and ESVE

Boxmeer, October 6, 2006 – Intervet presented two awards during ECVIM-CA annual congress and ESVE meeting, as part of its annual sponsorship program to encourage research in the fields of veterinary internal medicine and veterinary endocrinology.This year’s ECVIM-CA (European College of Veterinary Internal Medicine – Companion Animals) congress was held in Amsterdam, The Netherlands from September 14 to 16, 2006. Once again, this congress was remarkably successful in terms of participation, growing dramatically in size: in 1999 there were around 250 delegates and this year delegate numbers

New chemicals plants represent landmark for Akzo Nobel

Arnhem, the Netherlands, September 26, 2006 – When Akzo Nobel officially opens its two new chemicals plants in Delfzijl today it will mark the completion of the company’s biggest ever chemicals investment in the Netherlands.The construction of the chlorine and monochloroacetic acid (MCA) facilities—which involved the relocation of activities from Hengelo—saw the company commit a total of approximately EUR 200 million to the project, an outlay which has also signaled the end of Akzo Nobel’s regular Dutch chlorine transports. Supported by a EUR 65 million contribution from the Dutch

Intervet’s equine West Nile vaccine approved by USDA

Arnhem, the Netherlands, September 14, 2006 — An equine vaccine developed by Akzo Nobel’s animal health business Intervet, which is indicated for use in horses at risk from West Nile virus has been approved by the United States Department of Agriculture (USDA) for use in the United States.PreveNileTM is the first one-dose modified-live virus vaccine to be registered in the United States for the prevention of viremia (the presence of a virus in the blood) caused by West Nile virus (WNV) infection in horses. The virus—which can also be contracted by humans—is primarily spread by mosquitoes.

Akzo Nobel shareholders approve separation proposal

Arnhem, the Netherlands, September 7, 2006 — Akzo Nobel has moved a step closer to separating into two independent companies after shareholders approved the company’s proposal at an Extraordinary General Meeting (EGM).The EGM was called to ask shareholders to give their approval to the proposed separation, which will see the company separate into Akzo Nobel—active in coatings and chemicals— and Organon BioSciences, active in pharmaceuticals. Akzo Nobel intends to divest a minority stake in Organon BioSciences preferably through a listing of approximately 20 to 30 percent of Organon

Nobilon, BioDiem and leading U.S. scientists developing pandemic avian flu vaccine

Arnhem, the Netherlands, August 30, 2006 — Scientists at Akzo Nobel’s Nobilon International human vaccines business working to fight the threat of a global bird flu pandemic have received a major boost following the signing of a cooperative research and development agreement with the Centers for Disease Control and Prevention (CDC) in the United States.The agreement—co-signed with Nobilon’s international partner, Australian-based BioDiem Ltd—involves the development of a live attenuated cold-adapted cell culture vaccine against the H5N1 strain of the avian influenza virus. According to

Akzo Nobel announces EGM to approve separation of its Pharma business

Arnhem, the Netherlands, August 15, 2006 — Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) has announced that an Extraordinary General Meeting of Shareholders (EGM) is to be held on September 7 — in accordance with Dutch law — and has today published the relevant agenda and shareholders’ circular.At next month’s EGM, shareholders will be asked to give their approval to separate Akzo Nobel into two independent companies—Akzo Nobel, active in coatings and chemicals; and Organon BioSciences (OBS), active in pharmaceuticals. This proposal constitutes a significant change in the identity and

Akzo Nobel forms alliance with Feixiang Chemicals

Arnhem, the Netherlands, August 8, 2006 – Akzo Nobel has taken a significant step towards further strengthening its presence in the Asian chemicals market following an announcement that the company’s Surfactants business has formed a strategic alliance with Feixiang Chemicals (Zhangjiagang) Company, Ltd, China’s leading specialty surfactants supplier.Based in Jiangsu Province, Feixiang Chemicals manufactures various chemical products, including a full range of fatty amine and surfactant products with a total capacity of around 80,000 tons per year. The new 50/50 joint venture—which is

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media